PENNISI, MARIA STELLA
 Distribuzione geografica
Continente #
NA - Nord America 501
EU - Europa 383
AF - Africa 110
AS - Asia 90
OC - Oceania 1
SA - Sud America 1
Totale 1.086
Nazione #
US - Stati Uniti d'America 493
IT - Italia 174
IE - Irlanda 95
CI - Costa d'Avorio 74
CN - Cina 39
DE - Germania 34
SN - Senegal 34
VN - Vietnam 28
RU - Federazione Russa 21
BE - Belgio 12
GB - Regno Unito 9
CA - Canada 8
SE - Svezia 8
IN - India 6
UA - Ucraina 5
CH - Svizzera 4
FR - Francia 4
PL - Polonia 4
UZ - Uzbekistan 4
NO - Norvegia 3
TR - Turchia 3
ES - Italia 2
HK - Hong Kong 2
JP - Giappone 2
NG - Nigeria 2
NL - Olanda 2
SG - Singapore 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
AU - Australia 1
BG - Bulgaria 1
BR - Brasile 1
GR - Grecia 1
IL - Israele 1
LB - Libano 1
LU - Lussemburgo 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 1.086
Città #
Chandler 194
Dublin 95
Abidjan 74
Catania 51
Dakar 34
Ashburn 31
Cambridge 27
Lawrence 25
Andover 24
Grafing 23
Dong Ket 22
Wilmington 17
Des Moines 14
Brussels 12
Nanjing 10
Santa Venerina 9
Beijing 8
Palermo 8
Hanoi 6
Los Angeles 6
Pune 6
Milan 5
Seattle 5
Toronto 5
Bremen 4
Edinburgh 4
Falls Church 4
Giardini-Naxos 4
Houston 4
Jiaxing 4
Saint Petersburg 4
Boardman 3
Catanzaro 3
Fantina 3
Hanover 3
Oslo 3
Woodbridge 3
Abuja 2
Fairfield 2
Frankfurt am Main 2
Jacksonville 2
London 2
Madrid 2
Mascali 2
Messina 2
Moscow 2
Nanchang 2
Ottawa 2
Sant'Agata di Militello 2
Singapore 2
Siracusa 2
Tokyo 2
Aci Catena 1
Aci Sant'Antonio 1
Ann Arbor 1
Bangkok 1
Barcellona Pozzo di Gotto 1
Belgrade 1
Bratislava 1
Casamassima 1
Changsha 1
Chicago 1
Den Haag 1
Dubai 1
Gioiosa Marea 1
Groningen 1
Grosseto 1
Hebei 1
Jinan 1
Kocaeli 1
Luxembourg 1
Manchester 1
Melbourne 1
Montreal 1
New York 1
Ozieri 1
Piraino 1
Polska 1
Ramacca 1
Redmond 1
Redwood City 1
San Giovanni la Punta 1
Sindelfingen 1
Sofia 1
Spezzano Della Sila 1
São Paulo 1
Tel Aviv 1
Tianjin 1
Villamagna 1
Zhengzhou 1
Totale 825
Nome #
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 83
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 57
Activation of the IGF axis in thyroid cancer: Implications for tumorigenesis and treatment 57
B-ALL relapses after autologous stem cell transplantation associated with a shift from e1a2 to e14a2 BCR-ABL transcripts: A case report 51
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice 51
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 51
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 51
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 51
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 46
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 45
Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22) 45
Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report 44
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 44
New insights in thyroid cancer and p53 family proteins 43
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 42
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 41
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 38
The Role of New Technologies in Myeloproliferative Neoplasms 38
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias 38
Opportunities and challenges of liquid biopsy in thyroid cancer 36
Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma 35
Targeting BCL-2 as a therapeutic strategy for primary p210BCR-ABL1-positive B-ALL cells 33
Rapid decline of philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report 32
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 31
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes 29
Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports 26
Multiple primary malignances managed with surgical excision: a case report with next generation sequencing analysis 14
Totale 1.152
Categoria #
all - tutte 4.732
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.732


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201912 0 0 0 0 0 0 0 0 0 6 2 4
2019/2020107 21 2 5 10 9 8 3 12 1 5 10 21
2020/2021113 10 0 3 10 23 5 2 2 26 2 3 27
2021/2022184 1 33 6 3 37 4 30 6 7 1 12 44
2022/2023515 29 46 23 68 28 75 3 108 98 5 23 9
2023/2024210 21 49 11 9 10 76 2 19 2 11 0 0
Totale 1.152